Heska Corporation develops, manufactures, markets, sells, and supports veterinary products for the canine and feline companion animal health markets. It operates in two segments, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals, and Products. The Core Companion Animal Health segment offers veterinary diagnostic and other instruments, including handheld blood analyzers, veterinary chemistry analyzers, veterinary hematology analyzers, IV pumps, and consumable supplies; point-of-care diagnostic and other tests, such as heartworm diagnostic tests for dogs and cats, and early renal damage detection products; and veterinary diagnostic laboratory products and services, which comprise allergy diagnostic products and services, as well as ERD Reagent Packs used to detect microalbuminuria. It provides pharmaceuticals and supplements, such as heartworm prevention products, nutritional supplements, and hypothyroid treatment products; and vaccines and other biologicals for the treatment of allergies and feline respiratory diseases.This segment sells its products to veterinarians directly, as well as through telephone sales force, independent third party distributors, and other distribution relationships. The Other Vaccines, Pharmaceuticals, and Products segment provides private label vaccines and pharmaceuticals primarily for cattle, as well as for other animals, including small mammals and fish. It offers bovine vaccines, and biological and pharmaceutical products for other animal health companies, as well as provides turnkey services, which consist of research, licensing, production, labeling, and packaging of products, as well as validation support and distribution services. This segment sells its products through third parties under third party labels. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

OSI Pharmaceuticals, Inc. company was founded in 1983 and is based in Melville, New York. OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of molecular targeted therapies for the treatment of unmet medical needs in oncology, diabetes, and obesity. Its flagship product, Tarceva is a small molecule therapeutic designed to inhibit the receptor tyrosine kinase activity of the protein product of the HER1/EGFR gene. The company also offers Novantrone, a mitoxantrone for injection concentrate. OSI Pharmaceuticals products in Phase I clinical trials include OSI-906, an oral small molecule IGF-1R inhibitor for various cancers, including NSCLC, breast, pancreatic, prostate, colorectal, adrenocortical, and ovarian; PSN821, an oral small molecule drug with anti-diabetic and appetite suppressing effects developed for the treatment of type 2 diabetes; PSN602, a novel dual serotonin and noradrenaline reuptake inhibitor for the long-term treatment of obesity; and OSI-027, a small molecule TORC1/TORC2 inhibitor to supersede first generation mTOR inhibitors. The companys other development programs include OSI-296, a novel potent TKI developed to block compensatory signaling in epithelial tumor cells; OSI-930, a multi-targeted tyrosine kinase inhibitor that acts as a potent co-inhibitor of the receptor tyrosine kinases c-kit and the vascular endothelial growth factor receptor-2; OSI-632, an anti-angiogenesis agent; and CP-868,596, a PDGFR inhibitor. OSI Pharmaceuticals has collaboration agreements with Genentech, Inc.; Roche; and AVEO Pharmaceuticals, Inc.

Unicity distributes nutritional supplements and skin care products through a multilevel marketing network of some 350,000 independent contractors who sell direct to consumers. Unicity's products include Bios Life branded weight management products, and a variety of herbal remedies for allergies, anti-aging, diabetes, digestive problems, heart health, and stress reduction. Unicity was formed in 2001 when network marketing firms Rexall Showcase International and Enrich International merged. It operates offices in a dozen countries and sells its products in more than 20 countries.

BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama. BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS).Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited.

NutraCea is a health science company that has intellectual property that allows the Company to process and convert rice bran into a nutritious ingredient, stabilized rice bran that has applications in various food products and as components of formulations that have applications for treatment modalities in nutritional supplementation. It is also used as a stand-alone product that can be sold through non-related entities with distribution into the market place, both in the United States and internationally. These products include food supplements and medical foods. The Company operates in two segments: the NutraCea segment, which manufactures and distributes ingredients primarily derived from SRB, and the Irgovel segment, which consists of its rice-bran oil and fatted and de-fatted SRB manufacturing subsidiary in Pelotas, Brazil. In November 2009, the Company filed a voluntary petition for protection under Chapter 11 of the United States Bankrupt Code.

Dyadic International, Inc. (Dyadic) is an early-stage biotechnology company. The Company has operations in the United States, the Netherlands and Poland. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies and the sale of its enzymes. The Company is a holding company that holds all of Dyadic International (USA), Inc. (Dyadic-Florida). Dyadic-Florida owns all of Geneva Investment Holdings Limited, Dyadic Nederland BV, and Dyadic International Sp. z o.o. Dyadic’s R&D activities focus on its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes.

Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Pharmaceuticals is interested in. The drug development company is using cutting-edge RNA interference (RNAi) technology to develop small-interfering RNA (siRNA) molecules, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Pharmaceuticals is developing other candidates for ailments such as acute renal (kidney) failure, hearing loss, and dyslipidemia (a metabolic syndrome).

Purely Proteins doesn't mix your ordinary protein shake. Through its proprietary technology, the company purifies human proteins to accelerate biotherapeutic drug discovery and drug screening. Purely Proteins also operates a subscription-based online database of gene and protein information called TargetBASE, which gives chemists and biologists a summary of known and potential protein targets that may help in the discovery of therapies for diabetes, cancer, and Alzheimer's disease. The company conducts its research in conjunction with several business partners, including Abcam Ltd, Asahi Kasei, Cytomyx Limited, and Inhibox Ltd. CEO David Parry-Smith co-founded Purely Proteins in 2002.

Urigen Pharmaceuticals, Inc. (Urigen) is a specialty pharmaceutical company engaged in the development and commercialization of therapeutic products for urological disorders. The Company’s product pipeline includes URG101, for the treatment of Painful Bladder Syndrome (PBS), which has completed a Phase II double blinded, placebo controlled, multi-center trial, and URG301, targeting urethritis and nocturia. Urigen specializes in the development of products for patients with urological ailments including, specifically, the development of products for amelioration Painful Bladder Syndrome/Interstitial Cystitis (PBS or PBS/IC), Urethritis, Nocturia and Overactive Bladder (OAB). Urology represents a specialty pharmaceutical market of approximately 12,000 physicians in North America. Urologists treat a variety of ailments of the urinary tract including urinary tract infections, bladder cancer, overactive bladder, urgency and incontinence and interstitial cystitis, a subset of PBS.

Theratechnologies is pepped up on peptides. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Lead drug candidate tesamorelin is a growth hormone-releasing peptide that Theratechnologies believes can combat a variety of problems, including HIV-related lipodystrophy (the metabolic syndrome characterized by changes in distribution of adipose tissue), muscle wasting associated with chronic obstructive pulmonary disease, sleep maintenance insomnia, and immune dysfunction in elderly patients.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.